Imaging in targeted delivery of therapy to cancer

Dancey, Gairin; Begent, R. H. J.; Meyer, Tim

doi:10.1007/s11523-009-0119-8

Cited by 22 publications

(12 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies directed against tumor-specific epitopes have been shown to have great potential for tumor imaging (29). Recently, the potential of monovalent anti-EGFR nanobodies for tumor imaging using SPECT was examined and it was shown that the nanobodies home to EGFR-overexpressing tumors (6,30).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects

Water

Bagcı-Önder

Agarwal

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The deregulation of the epidermal growth factor receptor (EGFR) has a significant role in the progression of tumors. Despite the development of a number of EGFR-targeting agents that can arrest tumor growth, their success in the clinic is limited in several tumor types, particularly in the highly malignant glioblastoma multiforme (GBM). In this study, we generated and characterized EGFRspecific nanobodies (ENb) and imageable and proapoptotic ENb immunoconjugates released from stem cells (SC) to ultimately develop a unique EGFR-targeted therapy for GBM. We show that ENbs released from SCs specifically localize to tumors, inhibit EGFR signaling resulting in reduced GBM growth and invasiveness in vitro and in vivo in both established and primary GBM cell lines. We also show that ENb primes GBM cells for proapoptotic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Furthermore, SC-delivered immunoconjugates of ENb and TRAIL target a wide spectrum of GBM cell types with varying degrees of TRAIL resistance and significantly reduce GBM growth and invasion in both established and primary invasive GBM in mice. This study demonstrates the efficacy of SC-based EGFR targeted therapy in GBMs and provides a unique approach with clinical implications.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects

Water

Bagcı-Önder

Agarwal

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…In the future, other supplementary modules such as Imaging will be considered, given their role in therapy development [36]. …”

Section: Resultsmentioning

confidence: 99%

Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundBiology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.FindingsWe introduce the Guidelines for Information About Therapy Experiments (GIATE), a minimum information checklist creating a consistent framework to transparently report the purpose, methods and results of the therapeutic experiments. A discussion on the scope, design and structure of the guidelines is presented, together with a description of the intended audience. We also present complementary resources such as a classification scheme, and two alternative ways of creating GIATE information: an electronic lab notebook and a simple spreadsheet-based format. Finally, we use GIATE to record the details of the phase I clinical trial of CHT-25 for patients with refractory lymphomas. The benefits of using GIATE for this experiment are discussed.ConclusionsWhile data standards are being developed to facilitate data sharing and integration in various aspects of experimental medicine, such as genomics and clinical data, no previous work focused on therapy development. We propose a checklist for therapy experiments and demonstrate its use in the 131Iodine labeled CHT-25 chimeric antibody cancer therapy. As future work, we will expand the set of GIATE tools to continue to encourage its use by cancer researchers, and we will engineer an ontology to annotate GIATE elements and facilitate unambiguous interpretation and data integration.

show abstract

“…Radionuclides such as indium-111-octreotide are used for imaging prior to treatment of certain cancers [134,135].…”

Section: Nuclear Imagingmentioning

confidence: 99%

Applications of phototheranostic nanoagents in photodynamic therapy

et al. 2014

View full text Add to dashboard Cite

Nanotherapeutics has an increasing role in the treatment of diseases such as cancer. In photodynamic therapy (PDT) a therapeutically inactive photosensitizer compound is selectively activated by light to produce molecules capable of killing diseased cells and pathogens. A phototheranostic agent can be defined as a single nanoentity with the capabilities for targeted delivery, optical imaging and photodynamic treatment of a disease. Malignant cells, tissue and microbial etiologic agents can be effectively targeted by PDT. Photodynamic therapy is noninvasive, or minimally invasive, and has few side effects as damage to healthy tissue is minimized and the killing effect is localized. Various forms of cancer, acne and other diseases may be treated. The in vivo efficacy of photosensitizers is further improved by attaching them to nanostructures capable of targeting the diseased site. Such photosensitizer-functionalized nanostructures, or nanotherapeutics, allow site-specific delivery of imaging and therapeutic agents for improved phototheranostic performance. This review explores the potential applications of phototheranostic nanostructures in diagnosis and therapy.

show abstract

Imaging in targeted delivery of therapy to cancer

Cited by 22 publications

References 141 publications

Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects

Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects

Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy

Applications of phototheranostic nanoagents in photodynamic therapy

Contact Info

Product

Resources

About